Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis-Reference-Cited by-同舟云学术

Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis

Published:2023-06 Issue: Volume:22 Page:100506
ISSN:2667-193X
Container-title:The Lancet Regional Health - Americas
language:en
Short-container-title:The Lancet Regional Health - Americas

Author:

Ivama-Brummell Adriana M.^ORCID,Marciniuk Fernanda L.^ORCID,Wagner Anita K.^ORCID,Osorio-de-Castro Claudia G.S.^ORCID,Vogler Sabine^ORCID,Mossialos Elias^ORCID,Tavares-de-Andrade Carla L.^ORCID,Naci Huseyin^ORCID

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Internal Medicine,Health Policy

Reference28 articles.

1. Global oncology trends 2022,2022

2. Generating comparative evidence on new drugs and devices before approval;Naci;Lancet,2020

3. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012;Downing;JAMA,2014

4. Magnitude of clinical benefit of cancer drugs approved by the US food and drug administration;Tibau;J Natl Cancer Inst,2018

5. Potential cost implications for all US food and drug administration oncology drug approvals in 2018;Demartino;JAMA Intern Med,2020

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pricing, Procurement and Reimbursement Policies for Incentivizing Market Entry of Novel Antibiotics and Diagnostics: Learnings from 10 Countries Globally;Applied Health Economics and Health Policy;2024-06-05

2. Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway;Journal of Pharmaceutical Policy and Practice;2024-06-04

3. Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis;The Lancet Oncology;2024-06

4. International Cost-Effectiveness Analysis of Durvalumab in Stage III Non–Small Cell Lung Cancer;JAMA Network Open;2024-05-30

5. Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001–2020;The Lancet Regional Health - Western Pacific;2024-04